Abstract Drug resistance developed towards conventional therapy is one of the important reasons for chemotherapy failure in cancer. The various underlying mechanism for drug resistance development in tumor includes tumor heterogeneity, some cellular levels changes, genetic factors, and others novel mechanisms which have been highlighted in the past few years. In the present scenario, researchers have to focus on these novel mechanisms and their tackling...
Wed Jul 22, 2020 03:00
Background In a randomized study, glasdegib (a hedgehog inhibitor) plus low‐dose cytarabine (LDAC) significantly prolonged survival in comparison with LDAC in patients with acute myeloid leukemia (AML). A quality‐adjusted time without symptoms of disease progression or toxicity (Q‐TWiST) approach was used to evaluate comparative quality‐adjusted survival. Methods Overall survival was partitioned into the following: time with any treatment‐emergent grade 3 or higher adverse events (TOX); time...
Wed Jul 22, 2020 22:00
Background Because of the global spread of coronavirus disease 2019 (COVID‐19), oncology departments across the world have rapidly adapted their cancer care protocols to balance the risk of delaying cancer treatments and the risk of COVID‐19 exposure. COVID‐19 and associated changes may have an impact on the psychosocial functioning of patients with cancer and survivors. This study was designed to determine the impact of the COVID‐19 pandemic on young people living with and beyond cancer. Methods...
Wed Jul 22, 2020 16:55
Background The question of whether having a family history of prostatic borderline or in situ neoplasia (PBISN) is associated with an increased risk of invasive prostate cancer (PCa) or death from PCa remains unanswered. The objective of the current study was to provide an evidence‐based risk estimation for the relatives of patients with PBISN. Methods Nationwide Swedish family cancer data sets were used for the current study, including data regarding all residents of Sweden who were born...
Wed Jul 22, 2020 16:54
Background The prognostic impact of DNA mismatch repair (MMR) status remains controversial in patients with stage III colon cancer who are treated with adjuvant chemotherapy (AC). The aim of this study was to evaluate the survival outcome of AC in deficient mismatch repair (dMMR)/microsatellite instable (MSI) stage III CC. Methods Patients with pathological stage III CC between 2010 and 2013 were identified from the National Cancer Database using International Classification of Diseases for...
Wed Jul 22, 2020 16:54
Background Five‐year overall survival (OS) for patients with unresectable stage III non–small cell lung cancer (NSCLC) is poor. Until recently, a standard of care was concurrent chemoradiation alone. Patients with metastatic NSCLC treated with anti–programmed death 1 antibodies have demonstrated improved OS. This trial evaluated pembrolizumab as consolidation therapy after concurrent chemoradiation in patients with unresectable stage III disease. Methods Patients with unresectable stage III...
Wed Jul 22, 2020 16:53
Background Circulating blasts (peripheral blood [PB] blasts) ≥1% have long been considered an unfavorable feature for patients with primary myelofibrosis. Whether further quantification of PB blasts and their correlation with bone marrow (BM) blasts have incremental value with regard to patient prognostication is unclear. Similarly, the role of the JAK1/JAK2 inhibitor ruxolitinib (RUX) is not well defined in patients who have increased blasts. Methods The authors retrospectively studied 1316...
Wed Jul 22, 2020 16:52
Background Patients with ovarian cancer who are enrolled on phase 1 trials typically have platinum‐resistant and heavily pretreated disease, with a poor prognosis. In the current study, the authors assessed prognostic factors and survival in women with recurrent ovarian cancer who were treated on phase 1 clinical trials. Methods The authors performed a retrospective analysis of patients treated from 2008 through 2018 at the University of Colorado Cancer Center. Patient characteristics and...
Wed Jul 22, 2020 16:51
Background The clinical benefit and pricing of breakthrough‐designated cancer drugs are uncertain. This study compares the magnitude of the clinical benefit and monthly price of new and supplemental breakthrough‐designated and non–breakthrough‐designated cancer drug approvals. Methods A cross‐sectional cohort comprised approvals of cancer drugs for solid tumors from July 2012 to December 2017. For each indication, the clinical benefit from the pivotal trials was scored via validated frameworks:...
Wed Jul 22, 2020 16:50
Background Molecular testing of thyroid nodules with indeterminate fine‐needle aspiration (FNA) cytology is commonly used to guide patient management and is typically performed on freshly collected FNA samples. In this study, the authors evaluated the performance of the ThyroSeq test in cytology smear slides. Methods Air‐dried Diff‐Quik (DQ)‐stained and alcohol‐fixed Papanicolaou (Pap)‐stained smears were used to determine required cellularity and sensitivity of mutation detection and to compare...
Wed Jul 22, 2020 14:00
Abstract Comorbidities at diagnosis among patients with chronic myeloid leukemia in chronic phase (CML‐CP) may affect their overall survival (OS) rate even in the tyrosine kinase inhibitor (TKI) era. However, the prognostic impact of comorbidities in CML‐CP patients treated with a second‐generation TKI (2GTKI) has not been elucidated. We evaluated the effect of comorbidities on survival using the Charlson Comorbidity Index (CCI) in CML‐CP patients treated with imatinib or 2GTKI (nilotinib and dasatinib)....
Wed Jul 22, 2020 11:10
Publication date: August 2020Source: European Journal of Surgical Oncology, Volume 46, Issue 8Author(s):
Wed Jul 22, 2020 16:40
Publication date: August 2020Source: European Journal of Surgical Oncology, Volume 46, Issue 8Author(s):
Wed Jul 22, 2020 16:40
Publication date: August 2020Source: European Journal of Surgical Oncology, Volume 46, Issue 8Author(s):
Wed Jul 22, 2020 16:40
Publication date: Available online 22 July 2020Source: European Journal of Surgical OncologyAuthor(s): C. Lucy Dalton, Kristijonas Milinis, David Houghton, Paul Ridley, Katharine Davies, Richard Williams, David Hamilton, Mark D. Wilkie, Anne Markey, Kim Clarke, Matthew Lofthouse, Timothy R. Helliwell, Asterios Triantafyllou, Jennifer Rodrigues, Krishna Bheemireddy, Ged Dempsey, Rebecca Hanlon, Hulya Wieshmann, Anoop Haridass, Caroline Brammer
Wed Jul 22, 2020 16:40
Publication date: Available online 22 July 2020Source: European Journal of Surgical OncologyAuthor(s): Helen J.S. Jones, Issam Al-Najami, Chris Cunningham
Wed Jul 22, 2020 16:40
Future Oncology, Ahead of Print.
Tue Jul 21, 2020 06:15
Related Articles Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma. Future Oncol. 2020 Jul 21;: Authors: Jacob A, Shook J, Hutson TE Abstract The VHL mutation-HIF upregulation-VEGF transcription sequence is the principal pathway in the development of renal cell carcinoma. Tyrosine kinase inhibitors target the VEGF receptors to inhibit further growth of renal...
Wed Jul 22, 2020 16:58
Abstract Genetic heterogeneity is a well-recognized feature of hepatocellular carcinoma (HCC). The coexistence of multiple genetic alterations in the same HCC nodule contributes to explain why gene-targeted therapy has largely failed. Targeting of early genetic alterations could theoretically be a more effective therapeutic strategy preventing HCC. However, the failure of most targeted therapies has raised much perplexity regarding the role of genetic alterations in driving...
Wed Jul 22, 2020 03:00
Publication date: Available online 21 July 2020Source: Practical Radiation OncologyAuthor(s): Prithima R. Mosaly, Robert Adams, Gregg Tracton, John Dooley, Karthik Adapa, Joseph K. Nuamah, Lawrence B. Marks, Lukasz M. Mazur
Wed Jul 22, 2020 16:23
Cancer is a major cause of mortality and a societal burden, which poses a medical challenge to this day.[1] Lung cancer is one of the most common types of cancer with respect to incidence.[2] The relatively low survival of lung cancer in conjunction with treatment induced toxicity emphasizes the importance of considering prognosis before making treatment decisions.[1–7] Stage III non-small cell lung cancer (NSCLC) compromises a particularly difficult subgroup in this regard, because it represents...
Wed Jul 22, 2020 03:00
We read the article [1] “Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19” by Tchelebi et al with great interest. We commend the authors for providing guidance on various gastrointestinal malignancies during the COVID-19 pandemic. Notably, with regard to the treatment of locally advanced anal cancer, the authors recommend definitive chemoradiation (CRT). The concurrent chemotherapy regimen recommended per the authors is...
Wed Jul 22, 2020 03:00
Viruses have evolved in tandem with the organisms that they infect. Afflictions of the plant and animal kingdoms with viral infections have forced the host organism to evolve new or exploit existing systems to develop the countermeasures needed to offset viral insults. As one example, nonsense-mediated mRNA decay, a cellular quality-control mechanism ensuring the translational fidelity of mRNA transcripts, has been used to restrict virus replication in both plants and animals. In response, viruses...
Wed Jul 22, 2020 19:35
Publication date: Available online 21 July 2020Source: Surgical Oncology Clinics of North AmericaAuthor(s): Alessandro Brunelli, Michael R. Gooseman, Cecilia Pompili
Wed Jul 22, 2020 17:05
Publication date: Available online 21 July 2020Source: Surgical Oncology Clinics of North AmericaAuthor(s): Nicolas Zhou, Ravi Rajaram, Wayne L. Hofstetter
Wed Jul 22, 2020 17:05
Publication date: Available online 21 July 2020Source: Surgical Oncology Clinics of North AmericaAuthor(s): Feredun Azari, Greg Kennedy, Sunil Singhal
Wed Jul 22, 2020 17:05
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου